XCELL BIOLOGIX

XCELL BIOLOGIX™ is a global regenerative medicine company focused on innovative amnion derived technologies that could disrupt traditional painful and expensive treatment options for tissue regeneration and healing of chronic wounds and severe burns. On November 15, 2017, XCELL BIOLOGIX™ signed an exclusive worldwide licensing agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM), a research institute affiliated with Wake Forest School of Medicine, for development and commercialization rights for novel amnion derived technologies shown to accelerate wound closure and re-epithelialization for the protection, healing and repair of chronic wounds and severe burns... We are committed to delivering innovative, patented technologies to help accelerate wound closure and skin growth for patients, as well as providing tissue donors the opportunity to help improve another person's quality of life... Thus, there is a need for ready-to-use wound healing and tissue..

Primary location: Kennesaw United States